BroadBand Light for the Treatment of Dry Eye Disease

Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Dec 7, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a new treatment called broadband light for people with dry eye disease and meibomian gland dysfunction, which are conditions that can cause discomfort and vision problems due to insufficient moisture in the eyes. The researchers want to see if this light therapy can help improve symptoms and provide relief for patients who have not found success with other treatments.

To be eligible for this trial, participants must be between the ages of 65 and 74 or between 36 and 52 years old and have been diagnosed with dry eye disease and meibomian gland dysfunction. They should also have had ongoing symptoms even after trying at least one other treatment. However, there are some criteria that would exclude someone from participating, such as having certain recent treatments, specific medical conditions, or a history of certain eye surgeries. If you join the trial, you can expect to receive the broadband light treatment and be monitored for its effects on your eye health. This study is not yet recruiting participants, so there will be more information available soon on how to take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fitzpatrick Skin Type I-V
• • Must be diagnosed with Dry eye disease (DED) and meibomian gland dysfunction (MGD)
• • Persistent dry eye signs and or symptoms after at least one prior DED treatment modality
• Exclusion Criteria:
• • Prior Intense pulsed light treatment for DED within the past six months
• • Prior Meibomian gland treatment with a device for DED within the past three months
• • History of trauma-induced ocular surface disease (thermal burns, chemical burns)
• • Subject is pregnant
• • History of seizures
• • Having significant unprotected sun exposure within the treatment area
• • Use of Accutane within the last six months
• • Use of doxycycline in the last 1 month
• • Allergy to proparacaine or lidocaine
• • Having active herpes simplex virus infection within the treatment area
• • Laser eye surgery (LASIK) within the past twelve months
• • History of abnormal response to sunlight
• • Having an active medical condition that may affect normal healing
• • Having active infections or compromised immune system
• • History of basal cell carcinoma in the treatment area within the past twelve months
• • History of keloid scar formation